Germline testing for inherited genetic variants is recommended to many people with cancer, yet such useful testing is notably underutilized.

Most Americans use social media, making it a crucial tool in oncology, where new findings, biomarkers, treatments, and trials are presented.

Education about cancer clinical trials can increase trial enrollment by improving impressions, reducing fears, and raising awareness.

Choosing NGS first rather than Single-Gene Testing in cancer is a financially effective and diagnostically efficient strategy in many cases.

To enroll in clinical trials for targeted cancer therapies, people must be aware of them; thus, raising awareness is vital to enrollment.

A CMO is responsible for compound development success, so building awareness proactively and compliantly is critical for clinical trials.

Liquid biopsy for cancer is non-invasive and easily repeated, permitting molecular profiling and many other purposes with strong accuracy.

Clinical trials held in the UK have seen patient enrollment and trial numbers drop. Flexibility & creativity are needed to overcome issues.

Blood-based biomarkers (BBMs) hold promise for a fast, convenient, and simple means to accurately diagnose Alzheimer's Disease.

We compared awareness in oncologists of selected biomarkers to the prevalence of actionable oncogenic mutations across cancers.

We examined RAS/KRAS trending and awareness for oncologists; results track strongly with the history of scientific KRAS advancements.

We analyzed trending and awareness patterns of NTRK and NTRK-targeting compounds in academic and community oncologists.

Awareness of new and emerging cancer biomarkers and compounds is vital so HCPs will test for and treat molecular oncogenic drivers.